Skip to main content

Table 2 Adverse events reported in the included studies

From: Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis

Studies

Therapeutic regimen

Sample size

Infection

Gastrointestinal symptoms

Elevated liver enzymes

Blood system changes

Hair loss

Irregular menstruation

Total

Hogg 2015 [19]

MMF

23

0

2

0

0

0

0

2

Placebo

27

0

1

0

0

0

0

1

Liu 2014 [18]

MMF + prednisone

42

2

0

0

0

0

0

2

CTX + prednisone

42

2

3

1

1

1

3

11

Liu 2010 [17]

MMF + prednisone

20

0

0

1

0

0

0

1

LEF + prednisone

20

0

1

1

0

0

0

2

Bao 2007

MMF + prednisone

19

2

2

0

1

0

0

5

CTX + prednisone

18

3

4

1

2

2

2

13

Frich 2005

MMF

17

0

2

0

0

0

0

2

Placebo

15

0

2

0

1

0

0

3

Tang 2005 [13]

MMF

20

3

2

0

2

0

0

7

Placebo

20

0

0

0

0

0

0

0

Baes 2004

MMF

21

1

2

0

1

0

0

4

Placebo

13

0

0

0

0

0

0

0